Skip to main content

Table 2 Details of the disease stage, chemotherapy treatment and disease outcome of the 11 rectal cancer patients of our validation cohort

From: Calnexin, an ER-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer

Patient Stage Neo-adjuvant therpay RCPATH Outcome
1 III 50.4/28 + 5FU A Good
2 III 54.0/30 + 5FU A Good
3 III 50.4/28 + 5FU A Good
4 II 50.4/28 + 5FU A Good
5 III 50.4/28 + 5FU B Poor
6 III 50.4/28 + 5FU B Poor
7 III 50.4/28 + 5FU B Poor
8 III 50.4/28 + 5FU B Poor
9 III 50.4/28 + 5FU C Poor
10 III 50.4/28 + 5FU C Poor
11 II 50.4/28 + 5FU C Poor
  1. 5FU 5-fluorouracil; 50.4/28, total amount of 50.4 Gy radiotherapy in 28 fractions